Pfizer has selected a preclinical development candidate under its R&D collaboration with TCG Lifesciences Ltd. (TCGLS). Pfizer will own the candidate and other backup candidates and TCGLS will receive a success-based milestone payment.   The candidate is a small molecule new chemical entity that has met Pfizer’s criteria, including potency, pharmacokinetics, animal pharmacology, toxicology and related parameters. Mr. Swapan Bhattacharya, managing director, TCGLS, said, “We have established ...